These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 23575345)

  • 1. Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
    Kiage JN; Heimburger DC; Nyirenda CK; Wellons MF; Bagchi S; Chi BH; Koethe JR; Arnett DK; Kabagambe EK
    Lipids Health Dis; 2013 Apr; 12():50. PubMed ID: 23575345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
    Anastos K; Lu D; Shi Q; Tien PC; Kaplan RC; Hessol NA; Cole S; Vigen C; Cohen M; Young M; Justman J
    J Acquir Immune Defic Syndr; 2007 May; 45(1):34-42. PubMed ID: 17460470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
    Ngo-Giang-Huong N; Jourdain G; Amzal B; Sang-a-gad P; Lertkoonalak R; Eiamsirikit N; Tansuphasawasdikul S; Buranawanitchakorn Y; Yutthakasemsunt N; Mekviwattanawong S; McIntosh K; Lallemant M;
    PLoS One; 2011; 6(11):e27427. PubMed ID: 22132100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa.
    Manasa J; Lessells RJ; Skingsley A; Naidu KK; Newell ML; McGrath N; de Oliveira T;
    PLoS One; 2013; 8(8):e72152. PubMed ID: 23991055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
    Margot NA; Enejosa J; Cheng AK; Miller MD; McColl DJ;
    J Acquir Immune Defic Syndr; 2009 Oct; 52(2):209-21. PubMed ID: 19644384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda.
    Buchacz K; Weidle PJ; Moore D; Were W; Mermin J; Downing R; Kigozi A; Borkowf CB; Ndazima V; Brooks JT
    J Acquir Immune Defic Syndr; 2008 Mar; 47(3):304-11. PubMed ID: 18398971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
    Gallant JE; Staszewski S; Pozniak AL; DeJesus E; Suleiman JM; Miller MD; Coakley DF; Lu B; Toole JJ; Cheng AK;
    JAMA; 2004 Jul; 292(2):191-201. PubMed ID: 15249568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data.
    Price H; Asboe D; Pozniak A; Gazzard B; Fearnhill E; Pillay D; Dunn D; ;
    Antivir Ther; 2010; 15(2):203-11. PubMed ID: 20386075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
    Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
    N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.
    Havlir DV; Koelsch KK; Strain MC; Margot N; Lu B; Ignacio CC; Miller MD; Wong JK;
    J Infect Dis; 2005 Apr; 191(7):1164-8. PubMed ID: 15747253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
    Labhardt ND; Bader J; Lejone TI; Ringera I; Puga D; Glass TR; Klimkait T
    Trop Med Int Health; 2015 Jul; 20(7):914-8. PubMed ID: 25782332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.
    Okomo U; Togun T; Oko F; Peterson K; Townend J; Peterson I; Jaye A
    BMC Pediatr; 2012 Jul; 12():95. PubMed ID: 22770231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana.
    Nii-Trebi NI; Ibe S; Barnor JS; Ishikawa K; Brandful JA; Ofori SB; Yamaoka S; Ampofo WK; Sugiura W
    PLoS One; 2013; 8(8):e71972. PubMed ID: 23977189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).
    Shaffer D; Hughes MD; Sawe F; Bao Y; Moses A; Hogg E; Lockman S; Currier J
    J Acquir Immune Defic Syndr; 2014 Jun; 66(2):155-63. PubMed ID: 24562349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy.
    Madruga JR; Cassetti I; Suleiman JM; Etzel A; Zhong L; Holmes CB; Cheng AK; Enejosa J;
    HIV Clin Trials; 2007; 8(6):381-90. PubMed ID: 18042503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.
    Viganò A; Aldrovandi GM; Giacomet V; Merlo M; Martelli L; Beretta S; Luraschi P; Rombolà G; Mora S
    Antivir Ther; 2005; 10(8):917-24. PubMed ID: 16430197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R; Herrera L; Moreno S
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretrovirals for HIV Exposure Prophylaxis.
    Nikolopoulos G; Tsiodras S; Bonovas S; Hatzakis A
    Curr Med Chem; 2012; 19(35):5924-39. PubMed ID: 22963555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa.
    Wandeler G; Gerber F; Rohr J; Chi BH; Orrell C; Chimbetete C; Prozesky H; Boulle A; Hoffmann CJ; Gsponer T; Fox MP; Zwahlen M; Egger M;
    Antivir Ther; 2014; 19(5):521-5. PubMed ID: 24296645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
    Adedeji TA; Adebisi SA; Adedeji NO
    Infect Disord Drug Targets; 2020; 20(3):374-384. PubMed ID: 31389318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.